Content area
Full Text
A 36-year-old woman developed pulmonary hypertension and diffuse mediastinal fibrosis during treatment with bromocriptine and cabergoline [routes not stated].
The woman presented with a complaint of progressive exertional dyspnoea for six months and was referred for pulmonary endarterectomy with a suspected diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), for which she was on an anticoagulant therapy [specific drug not stated]. She was diagnosed with microprolactinoma seven years earlier for which she received low dose cabergoline 0.5 mg/week for one year and then switched to bromocriptine 2.5 mg/day as she wanted pregnancy. She was on bromocriptine for one year till pregnancy and her treatment was interrupted. She had a non-problematic pregnancy and childbirth, after which, she was resumed on low-dose carbergoline 0.5 mg/week. She had received a total dose of cabergoline 160mg and bromocriptine 900mg. She was a nonsmoker and was taking birth control pills for several years. Her heart rate was 97/min and BP was 125/80mm Hg. Clinical examination showed a systolic murmur and reduced breath sound in the right lung. The 6-min-walk-distance...